바이오의약품 발효 시스템 시장 : 제품 유형, 용도, 최종사용자 - 세계 예측(2024-2032년)

Global Biopharmaceutical Fermentation Systems Market will witness over 6% CAGR from 2024 to 2032, driven by the expansion of the biotechnology sector. As biotech companies continue developing new biologics and biosimilars, the need for high-quality fermentation systems intensifies. Against this backdrop, in May 2024, GE HealthCare launched Revolution RT at ESTRO 2024 in Glasgow. This AI-enhanced CT solution improves imaging accuracy and simplifies workflows, enhancing personalized oncology care. The company unveiled the updated iRT platform and MIM Software portfolio to address complex cancer diagnostics and treatment delays.

Biopharmaceutical fermentation systems are essential for producing complex biological drugs and achieving scalable, efficient manufacturing processes. The surge in biotech innovation and increased investment in R&D amplifies the demand for advanced fermentation technologies. These factors are supported by the growing focus on personalized medicine and novel therapeutic approaches, in turn favoring the market outlook.

The overall biopharmaceutical fermentation systems market is classified based on product type, end-user, application, and region.

The downstream products segment will register a notable CAGR through 2032, driven by a focus on post-production processing. Efficient downstream processing is crucial for purifying and formulating biopharmaceutical products, ensuring high quality. As biopharmaceutical companies emphasize optimizing these processes, the need for advanced fermentation systems grows. Additionally, the complexity of downstream product requirements necessitates sophisticated technologies that can handle diverse and challenging processing needs. The ongoing advancements in biopharmaceutical research and the increasing volume of drug development activities are further fueling the product adoption.

The antibiotics segment will garner a substantial biopharmaceutical fermentation systems market share by 2032, owing to the emphasis on developing effective antibiotics. As antibiotic resistance grows, there is a pressing demand for advanced fermentation technologies to produce novel antibiotics with enhanced efficacy. The manufacturing requires precise and scalable fermentation processes to ensure the consistent quality & yield of antibiotics. Additionally, the need to meet stringent regulatory standards and accelerate time-to-market for new antibiotics catapults the demand for sophisticated fermentation systems.

Europe biopharmaceutical fermentation systems market will record a considerable CAGR during 2024-2032, because of the strong emphasis on healthcare innovation and biotechnology. Europe is a leader in biopharmaceutical research, with numerous companies focusing on advanced therapies and personalized medicine. This commitment drives the need for sophisticated fermentation systems to support high-quality drug production. Strict regulatory standards for product safety, the increasing investment in biotechnology, and the growing demand for new treatments accelerate the market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing demand for biopharmaceuticals
    • 3.2.1.2 Growing investments for developing new biopharmaceuticals and biosimilars
    • 3.2.1.3 Increasing regulatory approvals for biopharmaceutical products
    • 3.2.1.4 Growing adoption of single use fermenters
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Requirements for high initial capital investments
    • 3.2.2.2 Issues related to extractables and leachables
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Gap analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Upstream products
  • 5.2.1 Bioreactors/fermenters
  • 5.2.2 Bioprocess analyzers
  • 5.2.3 Process monitoring systems
  • 5.2.4 Other upstream products
• 5.3 Downstream products
  • 5.3.1 Filtration & separation
  • 5.3.2 Chromatography
  • 5.3.3 Consumables & accessories
  • 5.3.4 Other downstream products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Recombinant proteins
• 6.3 Antibiotics
• 6.4 Probiotics
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End User, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Biopharmaceutical companies
• 7.3 Contract research organizations
• 7.4 Academic research institutes
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Agilent Technologies, Inc.
• 9.2 Becton, Dickinson and Company
• 9.3 Bioengineering AG
• 9.4 Cellexus Limited
• 9.5 Danaher Corporation
• 9.6 Eppendorf AG
• 9.7 F. Hoffmann-La Roche Ltd.
• 9.8 GE HealthCare Technologies, Inc.
• 9.9 Getinge Group
• 9.10 Lonza Group AG
• 9.11 Merck KGaA
• 9.12 Nova Biomedicals
• 9.13 Sartorius Stedim Biotech
• 9.14 Thermo Fisher Scientific Inc.
• 9.15 ZETA